Fuwai Central China Cardiovascular Hospital Becomes First to Offer Advanced Robotic Treatment for Heart Rhythm Disorders in Central China
“I am very proud of our team for successfully completing our first robotic ablation procedure in under one hour, an effort that would have had added risk and taken much longer with traditional, manual methods,” said
Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias. Robotic cardiac ablation is performed using a soft magnetic catheter navigated inside the heart by a physician seated at a computer cockpit. The physician navigates the catheter using precise, robotically actuated magnets positioned on either side of the patient.
“Our new robotic electrophysiology program helps us achieve our mission of providing the safest and most effective treatment options for patients suffering from cardiac arrhythmias,” said Hospital President, Professor
“We are delighted by the success of
About
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the
Stereotaxis Contacts:
Chairman and Chief Executive Officer
Chief Financial Officer
314-678-6100
investors@stereotaxis.com
Source: Stereotaxis, Inc.